Axl has been shown to increase EGFR-conferred chemoresistance in lung cancer [33], while it diversifies EGFR signalling and increased resistance to targeted therapy in triple negative breast cancer [34]. This evidence concerns the gene AXL and triple-negative breast carcinoma.